Samsung Biologics Shares Rally on Strong Growth: Key Insights Samsung Biologics stays a Buy: despite labor, legal, and quality recall risks, 2026.03 revenue rose 25.8% YoY and operating profit 35.0% YoY, supporting margin resilience and upside. 2026년 06월 02일 English
Samsung Electro-Mechanics Shares Rise on AI Parts Boom: Key Insight Samsung Electro-Mechanics shows strong AI-linked growth with revenue up 16.4% YoY and operating profit up 108% YoY; analysts rate it Buy, but investors must watch net income conversion versus a 35x valuation. 2026년 05월 07일 English
